Your browser doesn't support javascript.
loading
Molecular benchmarks of a SARS-CoV-2 epidemic.
Jonsson, Hakon; Magnusson, Olafur T; Melsted, Pall; Berglund, Jonas; Agustsdottir, Arna B; Eiríksdottir, Berglind; Fridriksdottir, Run; Garðarsdottir, Elisabet Eir; Georgsson, Gudmundur; Gretarsdottir, Olafia S; Guðmundsson, Kjartan R; Gunnarsdottir, Thora Rosa; Eggertsson, Hannes; Gylfason, Arnaldur; Holm, Hilma; Jensson, Brynjar O; Jonasdottir, Aslaug; Jonsson, Frosti; Josefsdottir, Kamilla S; Thordardottir, Marianna; Kristinsson, Karl G; Kristjánsson, Þórður; Magnusdottir, Droplaug N; Roux, Louise le; Saemundsdottir, Jona; Sigurdsson, Asgeir; Sigmundsdottir, Gudrun; Sveinbjornsson, Gardar; Rognvaldsson, Solvi; Eiriksson, Ogmundur; Magnusson, Magnus Karl; Sveinsdottir, Kristin Eva; Sveinsdottir, Maney; Thorarensen, Emil Aron; Thorbjornsson, Bjarni; Löve, Arthur; Norddahl, Gudmundur L; Jonsdottir, Ingileif; Sulem, Patrick; Masson, Gisli; Moller, Alma; Gudnason, Thorolfur; Kristjansson, Mar; Helgason, Agnar; Gudbjartsson, Daniel F; Thorsteinsdottir, Unnur; Stefansson, Kari.
Afiliação
  • Jonsson H; deCODE genetics/Amgen, Inc., Reykjavik, Iceland.
  • Magnusson OT; deCODE genetics/Amgen, Inc., Reykjavik, Iceland.
  • Melsted P; deCODE genetics/Amgen, Inc., Reykjavik, Iceland.
  • Berglund J; School of Engineering and Natural Sciences, University of Iceland, Reykjavik, Iceland.
  • Agustsdottir AB; deCODE genetics/Amgen, Inc., Reykjavik, Iceland.
  • Eiríksdottir B; deCODE genetics/Amgen, Inc., Reykjavik, Iceland.
  • Fridriksdottir R; deCODE genetics/Amgen, Inc., Reykjavik, Iceland.
  • Garðarsdottir EE; deCODE genetics/Amgen, Inc., Reykjavik, Iceland.
  • Georgsson G; deCODE genetics/Amgen, Inc., Reykjavik, Iceland.
  • Gretarsdottir OS; deCODE genetics/Amgen, Inc., Reykjavik, Iceland.
  • Guðmundsson KR; Landspitali University Hospital, Reykjavik, Iceland.
  • Gunnarsdottir TR; deCODE genetics/Amgen, Inc., Reykjavik, Iceland.
  • Eggertsson H; Landspitali University Hospital, Reykjavik, Iceland.
  • Gylfason A; deCODE genetics/Amgen, Inc., Reykjavik, Iceland.
  • Holm H; deCODE genetics/Amgen, Inc., Reykjavik, Iceland.
  • Jensson BO; deCODE genetics/Amgen, Inc., Reykjavik, Iceland.
  • Jonasdottir A; deCODE genetics/Amgen, Inc., Reykjavik, Iceland.
  • Jonsson F; deCODE genetics/Amgen, Inc., Reykjavik, Iceland.
  • Josefsdottir KS; deCODE genetics/Amgen, Inc., Reykjavik, Iceland.
  • Thordardottir M; Directorate of health, Reykjavik, Iceland.
  • Kristinsson KG; Directorate of health, Reykjavik, Iceland.
  • Kristjánsson Þ; Landspitali University Hospital, Reykjavik, Iceland.
  • Magnusdottir DN; deCODE genetics/Amgen, Inc., Reykjavik, Iceland.
  • Roux LL; deCODE genetics/Amgen, Inc., Reykjavik, Iceland.
  • Saemundsdottir J; deCODE genetics/Amgen, Inc., Reykjavik, Iceland.
  • Sigurdsson A; deCODE genetics/Amgen, Inc., Reykjavik, Iceland.
  • Sigmundsdottir G; deCODE genetics/Amgen, Inc., Reykjavik, Iceland.
  • Sveinbjornsson G; Directorate of health, Reykjavik, Iceland.
  • Rognvaldsson S; deCODE genetics/Amgen, Inc., Reykjavik, Iceland.
  • Eiriksson O; deCODE genetics/Amgen, Inc., Reykjavik, Iceland.
  • Magnusson MK; deCODE genetics/Amgen, Inc., Reykjavik, Iceland.
  • Sveinsdottir KE; deCODE genetics/Amgen, Inc., Reykjavik, Iceland.
  • Sveinsdottir M; deCODE genetics/Amgen, Inc., Reykjavik, Iceland.
  • Thorarensen EA; Landspitali University Hospital, Reykjavik, Iceland.
  • Thorbjornsson B; deCODE genetics/Amgen, Inc., Reykjavik, Iceland.
  • Löve A; deCODE genetics/Amgen, Inc., Reykjavik, Iceland.
  • Norddahl GL; Landspitali University Hospital, Reykjavik, Iceland.
  • Jonsdottir I; deCODE genetics/Amgen, Inc., Reykjavik, Iceland.
  • Sulem P; deCODE genetics/Amgen, Inc., Reykjavik, Iceland.
  • Masson G; Landspitali University Hospital, Reykjavik, Iceland.
  • Moller A; deCODE genetics/Amgen, Inc., Reykjavik, Iceland.
  • Gudnason T; deCODE genetics/Amgen, Inc., Reykjavik, Iceland.
  • Kristjansson M; Directorate of health, Reykjavik, Iceland.
  • Helgason A; Directorate of health, Reykjavik, Iceland.
  • Gudbjartsson DF; Landspitali University Hospital, Reykjavik, Iceland.
  • Thorsteinsdottir U; deCODE genetics/Amgen, Inc., Reykjavik, Iceland.
  • Stefansson K; Department of Anthropology, University of Iceland, Reykjavik, Iceland.
Nat Commun ; 12(1): 3633, 2021 06 15.
Article em En | MEDLINE | ID: mdl-34131116
ABSTRACT
A pressing concern in the SARS-CoV-2 epidemic and other viral outbreaks, is the extent to which the containment measures are halting the viral spread. A straightforward way to assess this is to tally the active cases and the recovered ones throughout the epidemic. Here, we show how epidemic control can be assessed with molecular information during a well characterized epidemic in Iceland. We demonstrate how the viral concentration decreased in those newly diagnosed as the epidemic transitioned from exponential growth phase to containment phase. The viral concentration in the cases identified in population screening decreased faster than in those symptomatic and considered at high risk and that were targeted by the healthcare system. The viral concentration persists in recovering individuals as we found that half of the cases are still positive after two weeks. We demonstrate that accumulation of mutations in SARS-CoV-2 genome can be exploited to track the rate of new viral generations throughout the different phases of the epidemic, where the accumulation of mutations decreases as the transmission rate decreases in the containment phase. Overall, the molecular signatures of SARS-CoV-2 infections contain valuable epidemiological information that can be used to assess the effectiveness of containment measures.
Assuntos

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Benchmarking / Epidemias / SARS-CoV-2 / COVID-19 Idioma: En Ano de publicação: 2021 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Benchmarking / Epidemias / SARS-CoV-2 / COVID-19 Idioma: En Ano de publicação: 2021 Tipo de documento: Article